Online citations, reference lists, and bibliographies.
← Back to Search

The Immune Microenvironment In Mesothelioma: Mechanisms Of Resistance To Immunotherapy

G. Chu, Nico van Zandwijk, J. E. J. Rasko
Published 2019 · Medicine

Cite This
Download PDF
Analyze on Scholarcy
Share
Although mesothelioma is the consequence of a protracted immune response to asbestos fibers and characterized by a clear immune infiltrate, novel immunotherapy approaches show less convincing results as compared to those seen in melanoma and non-small cell lung cancer. The immune suppressive microenvironment in mesothelioma is likely contributing to this therapy resistance. Therefore, it is important to explore the characteristics of the tumor microenvironment for explanations for this recalcitrant behavior. This review describes the stromal, cytokine, metabolic, and cellular milieu of mesothelioma, and attempts to make connection with the outcome of immunotherapy trials.
This paper references
10.18632/oncotarget.25004
Targeting Tie-2/angiopoietin axis in experimental mesothelioma confers differential responses and raises predictive implications
Sophia F Magkouta (2018)
past results and recent developments
S Tomek (2003)
HIF1alpha regulates function and differentiation of myeloid-derived suppressor cells in the tumor microenvironment
CA Corzo (2010)
a phase I clinical trial of malignant pleural disease treated with regionally delivered autologous mesothelin-targeted CAR T cells: safety and efficacy
PS Adusumilli (2019)
Expression and prognostic significance of hypoxia - inducible factor 1 alpha ( HIF - 1 alpha ) in malignant pleural mesothelioma ( MPM )
A Klabatsa (2006)
recent progress and potential biomarkers
P Darvin (2018)
10.1016/S1470-2045(18)30765-4
Nivolumab or nivolumab plus ipilimumab in patients with relapsed malignant pleural mesothelioma (IFCT-1501 MAPS2): a multicentre, open-label, randomised, non-comparative, phase 2 trial.
A. Scherpereel (2019)
10.1016/j.bjorl.2017.06.001
The meta-analysis.
F. Ribeiro (2017)
10.1002/cncr.26143
Circulating and tumor‐infiltrating myeloid cells predict survival in human pleural mesothelioma
B. Burt (2011)
10.1038/nm1609
Altered recognition of antigen is a mechanism of CD8+ T cell tolerance in cancer
S. Nagaraj (2007)
10.1016/S0002-9440(10)62492-3
Identification of novel candidate oncogenes and tumor suppressors in malignant pleural mesothelioma using large-scale transcriptional profiling.
G. Gordon (2005)
10.1186/1743-8977-7-5
Asbestos, carbon nanotubes and the pleural mesothelium: a review of the hypothesis regarding the role of long fibre retention in the parietal pleura, inflammation and mesothelioma
K. Donaldson (2009)
10.1155/2018/2438598
Natural Killer Cells from Malignant Pleural Effusion Are Endowed with a Decidual-Like Proangiogenic Polarization
Annalisa Bosi (2018)
10.1038/srep32992
PI3 Kinase Pathway and MET Inhibition is Efficacious in Malignant Pleural Mesothelioma
R. Kanteti (2016)
10.1016/j.jtcvs.2007.10.026
Impact of tumor-infiltrating T cells on survival in patients with malignant pleural mesothelioma.
Masaki Anraku (2008)
10.1002/ijc.32363
NK‐ and T‐cell subsets in malignant mesothelioma patients: Baseline pattern and changes in the context of anti‐CTLA‐4 therapy
Rosa Sottile (2019)
10.1155/2018/5804230
Complex Immune Contextures Characterise Malignant Peritoneal Mesothelioma: Loss of Adaptive Immunological Signature in the More Aggressive Histological Types
M. Tazzari (2018)
10.1084/jem.20111653
TGF-β synergizes with defects in the Hippo pathway to stimulate human malignant mesothelioma growth
M. Fujii (2012)
10.1080/2162402X.2016.1261241
Prognostic and predictive aspects of the tumor immune microenvironment and immune checkpoints in malignant pleural mesothelioma
E. Marcq (2017)
10.1002/path.2829
The expression of CXCR4, CXCL12 and CXCR7 in malignant pleural mesothelioma
T. Li (2011)
Abstract CT 036 : a phase I clinical trial of malignant pleural disease treated with regionally delivered autologous mesothelin - targeted CAR T cells : safety and efficacy
PS Adusumilli
10.1371/journal.pone.0007016
Global Gene Expression Profiling Of Human Pleural Mesotheliomas: Identification of Matrix Metalloproteinase 14 (MMP-14) as Potential Tumour Target
S. Crispi (2009)
10.3892/IJO_00000180
Differential effects of malignant mesothelioma cells on THP-1 monocytes and macrophages.
V. Izzi (2009)
10.1158/1535-7163.MCT-07-0579
Targeting tumor-associated macrophages in an orthotopic murine model of diffuse malignant mesothelioma
N. Miselis (2008)
10.1038/ncomms12150
Recommendations for myeloid-derived suppressor cell nomenclature and characterization standards
V. Bronte (2016)
10.1054/bjoc.2001.1997
Angiogenesis is an independent prognostic factor in malignant mesothelioma
J. Edwards (2001)
Activated granulocytes and granulocyte-derived hydrogen peroxide are the underlying mechanism of suppression of t-cell function in advanced cancer patients.
J. Schmielau (2001)
Results from the European Thoracic Oncology Platform (ETOP 9-15) PROMISE-meso trial
S Popat (2019)
10.1038/nature10169
Tumour hypoxia promotes tolerance and angiogenesis via CCL28 and Treg cells
A. Facciabene (2011)
10.1158/1078-0432.CCR-11-0351
Expression of a Functional CCR2 Receptor Enhances Tumor Localization and Tumor Eradication by Retargeted Human T cells Expressing a Mesothelin-Specific Chimeric Antibody Receptor
Edmund K. Moon (2011)
10.1126/scitranslmed.3003130
The PDL1-PD1 Axis Converts Human TH1 Cells into Regulatory T Cells
S. Amarnath (2011)
10.1016/j.ajpath.2011.05.060
Pleural mesothelioma instigates tumor-associated fibroblasts to promote progression via a malignant cytokine network.
Q. Li (2011)
10.1038/cddis.2014.136
Autocrine CSF-1R signaling drives mesothelioma chemoresistance via AKT activation
M. Cioce (2014)
10.1093/intimm/dxs005
IL-2/CD40-driven NK cells install and maintain potency in the anti-mesothelioma effector/memory phase.
C. Jackaman (2012)
10.1136/thoraxjnl-2017-211416
Introducing the new BTS guideline: the investigation and management of pleural malignant mesothelioma
I. Woolhouse (2018)
10.4161/cbt.4.3.1644
Regulatory T cells and cytokines in malignant pleural effusions secondary to mesothelioma and carcinoma
P. Delong (2005)
Chrysotile fiber is a strong mutagen in mammalian cells.
T. Hei (1992)
10.1016/j.lungcan.2015.07.015
Characterization of hypoxia in malignant pleural mesothelioma with FMISO PET-CT.
R. Francis (2015)
Prognostic and predictive aspects of the tumor immune microenvironment and immune checkpoints in malignant pleural mesothelioma. Oncoimmunology
E Marcq (2017)
10.1038/s41573-018-0004-1
Turning foes to friends: targeting cancer-associated fibroblasts
Xueman Chen (2018)
10.1080/019021400404528
Asbestos exposure induces MCP-1 secretion by pleural mesothelial cells.
S. Tanaka (2000)
10.1016/J.JTHO.2016.11.1519
P2.06-026 A Phase II Trial of the Oral FGF Receptor Inhibitor AZD4547 as 2nd or 3rd Line Therapy in Malignant Pleural Mesothelioma - Trial in Progress: Topic: Mesothelioma and SCLC
Wei-Sen Lam (2017)
10.1016/S1470-2045(17)30169-9
Clinical safety and activity of pembrolizumab in patients with malignant pleural mesothelioma (KEYNOTE-028): preliminary results from a non-randomised, open-label, phase 1b trial.
E. Alley (2017)
10.1309/AJCP5KNL7QTELLYI
Comparative immunohistochemical analysis of IMP3, GLUT1, EMA, CD146, and desmin for distinguishing malignant mesothelioma from reactive mesothelial cells.
H. Minato (2014)
10.1038/s41598-018-28297-x
Pirfenidone decreases mesothelioma cell proliferation and migration via inhibition of ERK and AKT and regulates mesothelioma tumor microenvironment in vivo
C. Li (2018)
10.1016/J.BBRC.2006.03.018
Intra-tumoural regulatory T cells: a potential new target in cancer immunotherapy.
D. J. Needham (2006)
10.1371/journal.pone.0106742
Ratio of Intratumoral Macrophage Phenotypes Is a Prognostic Factor in Epithelioid Malignant Pleural Mesothelioma
R. Cornelissen (2014)
10.1158/0008-5472.CAN-10-1439
Macrophage expression of hypoxia-inducible factor-1 alpha suppresses T-cell function and promotes tumor progression.
A. Doedens (2010)
10.1083/JCB1964OIA4
TGF-b synergizes with defects in the Hippo pathway to stimulate human malignant mesothelioma growth
M. Fujii (2012)
10.1038/ncomms9792
Fibrocyte-like cells mediate acquired resistance to anti-angiogenic therapy with bevacizumab
A. Mitsuhashi (2015)
10.1006/ABBI.1996.0059
Participation of nitric oxide and iron in the oxidation of DNA in asbestos-treated human lung epithelial cells.
C. Chao (1996)
PDL1 is a novel direct target of HIF-1alpha, and its blockade under hypoxia enhanced MDSC-mediated T cell activation
MZ Noman (2014)
10.18632/oncotarget.21113
Abundant expression of TIM-3, LAG-3, PD-1 and PD-L1 as immunotherapy checkpoint targets in effusions of mesothelioma patients
E. Marcq (2017)
10.1371/journal.pone.0121071
Analysis of Expression of Programmed Cell Death 1 Ligand 1 (PD-L1) in Malignant Pleural Mesothelioma (MPM)
S. Cedrés (2015)
10.1038/ng.3520
Comprehensive genomic analysis of malignant pleural mesothelioma identifies recurrent mutations, gene fusions and splicing alterations
R. Bueno (2016)
10.1016/j.chest.2016.01.001
Longitudinal Measurement of Pleural Fluid Biochemistry and Cytokines in Malignant Pleural Effusions.
Rajesh Thomas (2016)
10.1002/(SICI)1097-0215(19980413)76:2<240::AID-IJC12>3.0.CO;2-G
Hepatocyte growth factor/scatter factor stimulates chemotaxis and growth of malignant mesothelioma cells through c‐met receptor
J. Klominek (1998)
10.1371/journal.pone.0104848
Increased Levels of C-C Chemokine RANTES in Asbestos Exposed Workers and in Malignant Mesothelioma Patients from an Hyperendemic Area
M. Comar (2014)
10.1002/(SICI)1096-9896(199909)189:1<72::AID-PATH401>3.0.CO;2-0
Angiogenic cytokines in mesothelioma: a study of VEGF, FGF‐1 and ‐2, and TGF β expression
S. Kumar-Singh (1999)
10.1038/nri3064
The parallel lives of angiogenesis and immunosuppression: cancer and other tales
Gregory T. Motz (2011)
a randomised, controlled, open-label, phase 3 trial
G Zalcman (2016)
10.18632/ONCOTARGET.2731
Zoledronic acid overcomes chemoresistance and immunosuppression of malignant mesothelioma
I. C. Salaroglio (2015)
10.1016/S0002-9440(10)65698-2
TNF-alpha receptor knockout mice are protected from the fibroproliferative effects of inhaled asbestos fibers.
J. Y. Liu (1998)
Expression and prognostic significance of hypoxia-inducible factor 1alpha (HIF-1alpha) in malignant pleural mesothelioma (MPM). Lung Cancer
A Klabatsa (2006)
10.1073/pnas.0604008103
TNF-α inhibits asbestos-induced cytotoxicity via a NF-κB-dependent pathway, a possible mechanism for asbestos-induced oncogenesis
H. Yang (2006)
Transforming growth factor-beta 1 (TGF-beta 1)- and beta 2-like activities in malignant pleural effusions caused by malignant mesothelioma or primary lung cancer.
J. Maeda (1994)
10.1038/s12276-018-0191-1
Immune checkpoint inhibitors: recent progress and potential biomarkers
Pramod Darvin (2018)
Natural killer cells from malignant pleural effusion are endowed with a deciduallike proangiogenic polarization
A Bosi (2018)
Mesothelioma and tumor-associated autoantibodies. D31 Nonpulmonary critical care and monitoring
C J Chapman (2011)
10.1007/s12199-016-0530-6
Prognostic value of the lymphocyte-to-monocyte ratio and other inflammatory markers in malignant pleural mesothelioma
A. C. Tanrıkulu (2016)
10.1038/sj.bjc.6600673
Chemotherapy for malignant pleural mesothelioma: past results and recent developments
S. Tomek (2003)
10.1097/JTO.0b013e31824c9272
CCL2, Galectin-3, and SMRP Combination Improves the Diagnosis of Mesothelioma in Pleural Effusions
C. Blanquart (2012)
10.1038/s41416-018-0313-5
VISTA expressed in tumour cells regulates T cell function
Kumuluzi Mulati (2018)
10.1002/(SICI)1097-0215(19970917)72:6<1034::AID-IJC19>3.0.CO;2-4
Differential motile response of human malignant mesothelioma cells to fibronectin, laminin and collagen type IV: The role of β1 integrins
J. Klominek (1997)
10.1016/j.jtho.2016.06.022
Pleural Effusions from Patients with Mesothelioma Induce Recruitment of Monocytes and Their Differentiation into M2 Macrophages
Anne-Laure Chéné (2016)
10.5858/arpa.2017-0124-RA
Guidelines for Pathologic Diagnosis of Malignant Mesothelioma 2017 Update of the Consensus Statement From the International Mesothelioma Interest Group.
A. Husain (2018)
10.1126/scitranslmed.3010162
Regional delivery of mesothelin-targeted CAR T cell therapy generates potent and long-lasting CD4-dependent tumor immunity
P. Adusumilli (2014)
Phase II trial of pembrolizumab (P) in patients (pts) with previouslytreated mesothelioma (MM)
A Desai (2018)
10.1016/j.immuni.2016.01.021
Distinct Signaling of Coreceptors Regulates Specific Metabolism Pathways and Impacts Memory Development in CAR T Cells.
O. Kawalekar (2016)
10.1016/j.anndiagpath.2016.04.007
c-Met expression and MET amplification in malignant pleural mesothelioma.
Melanie C. Bois (2016)
10.1038/sj.bjc.6600920
Matrix metalloproteinases 2 and 9 (gelatinases A and B) expression in malignant mesothelioma and benign pleura
J. Edwards (2003)
10.1183/09031936.06.00135305
Mesothelioma environment comprises cytokines and T-regulatory cells that suppress immune responses
J. Hegmans (2006)
a double-blind, randomised, placebo-controlled phase 3 trial
GV Scagliotti (2019)
10.1164/rccm.201404-0658OC
Fibroblast growth factor receptor inhibition is active against mesothelioma and synergizes with radio- and chemotherapy.
K. Schelch (2014)
10.1016/S0169-5002(98)00014-2
Sera from patients with malignant mesothelioma can contain autoantibodies.
C. Robinson (1998)
10.1038/nrc2344
Hypoxia and metabolism: Hypoxia, DNA repair and genetic instability
R. Bristow (2008)
10.1016/j.lungcan.2015.03.005
Demographics, management and survival of patients with malignant pleural mesothelioma in the National Lung Cancer Audit in England and Wales.
P. Beckett (2015)
10.1016/j.bbagen.2016.09.031
Quantitative analysis of the role of fiber length on phagocytosis and inflammatory response by alveolar macrophages.
Trudy J. Padmore (2017)
10.1101/182980
How asbestos drives the tissue towards tumors: YAP activation, macrophage and mesothelial precursor recruitment, RNA editing and somatic mutations
H. Rehrauer (2017)
preliminary results from a nonrandomised, open-label, phase 1b trial
EW Alley (2017)
10.1038/s42003-018-0137-0
Origin of cancer-associated fibroblasts and tumor-associated macrophages in humans after sex-mismatched bone marrow transplantation
Masako Kurashige (2018)
10.1097/JTO.0b013e3181989ddb
Tryptase Mast Cells in Malignant Pleural Mesothelioma as an Independent Favorable Prognostic Factor
G. Alí (2009)
Chemotaxis and haptotaxis of human malignant mesothelioma cells: effects of fibronectin, laminin, type IV collagen, and an autocrine motility factor-like substance.
J. Klominek (1993)
10.1038/s41591-018-0290-5
Calibration of CAR activation potential directs alternative T cell fates and therapeutic potency
J. Feucht (2018)
cancer and other tales
GT Motz (2011)
10.1016/S1470-2045(17)30446-1
Tremelimumab as second-line or third-line treatment in relapsed malignant mesothelioma (DETERMINE): a multicentre, international, randomised, double-blind, placebo-controlled phase 2b trial.
M. Maio (2017)
10.1200/JCO.2018.36.15_SUPPL.8565
Phase II trial of pembrolizumab (P) in patients (pts) with previously-treated mesothelioma (MM).
A. Desai (2018)
10.1016/j.lungcan.2011.11.014
Vatalanib in malignant mesothelioma: a phase II trial by the Cancer and Leukemia Group B (CALGB 30107).
T. Jahan (2012)
10.1080/2162402X.2019.1601482
Targeting the C-terminus of galectin-9 induces mesothelioma apoptosis and M2 macrophage depletion
P. Bertino (2019)
10.1084/jem.20100587
HIF-1α regulates function and differentiation of myeloid-derived suppressor cells in the tumor microenvironment
C. Corzo (2010)
10.1073/pnas.1006542107
Programmed necrosis induced by asbestos in human mesothelial cells causes high-mobility group box 1 protein release and resultant inflammation
H. Yang (2010)
10.1158/1078-0432.CCR-17-3757
Tumor-Derived GM-CSF Promotes Granulocyte Immunosuppression in Mesothelioma Patients
Swati Khanna (2018)
10.1038/nrc2444
The role of myeloid cells in the promotion of tumour angiogenesis
C. Murdoch (2008)
targeting cancerassociated fibroblasts
X Chen (2019)
10.18632/oncotarget.25100
Four immunohistochemical assays to measure the PD-L1 expression in malignant pleural mesothelioma
T. Watanabe (2018)
10.1510/icvts.2009.223255
Multimodality treatment of malignant pleural mesothelioma with or without immunotherapy: does it change anything?
M. Lucchi (2010)
10.1016/j.ajpath.2010.12.014
Identification of novel markers for the diagnosis of malignant pleural mesothelioma.
F. Gueugnon (2011)
Audit in England and Wales
AN Husain (2015)
The PDL1PD1 axis converts human TH1 cells into regulatory T cells
S Amarnath (2011)
10.1080/2162402X.2017.1373235
The “don't eat me” signal CD47 is a novel diagnostic biomarker and potential therapeutic target for diffuse malignant mesothelioma
C. Schürch (2017)
10.1080/2162402X.2016.1278330
Integrated analysis of somatic mutations and immune microenvironment in malignant pleural mesothelioma
K. Kiyotani (2017)
10.1136/thoraxjnl-2017-211321
British Thoracic Society Guideline for the investigation and management of malignant pleural mesothelioma
I. Woolhouse (2018)
10.1158/2326-6066.CIR-16-0171
Cytotoxic T Cells in PD-L1–Positive Malignant Pleural Mesotheliomas Are Counterbalanced by Distinct Immunosuppressive Factors
M. Awad (2016)
10.1016/j.jtho.2017.09.1968
Molecular and Histopathological Characterization of the Tumor Immune Microenvironment in Advanced Stage of Malignant Pleural Mesothelioma
N. S. Patil (2018)
10.1152/AJPLUNG.1995.268.3.L471
Asbestos causes DNA strand breaks in cultured pulmonary epithelial cells: role of iron-catalyzed free radicals.
D. Kamp (1995)
10.1164/rccm.200811-1729OC
Clinical impact and reliability of pleural fluid mesothelin in undiagnosed pleural effusions.
H. E. Davies (2009)
10.1084/jem.20131916
PD-L1 is a novel direct target of HIF-1α, and its blockade under hypoxia enhanced MDSC-mediated T cell activation
M. Noman (2014)
10.1016/j.jtho.2018.08.007
Pembrolizumab as Palliative Immunotherapy in Malignant Pleural Mesothelioma
Y. Metaxas (2018)
10.1002/eji.201242783
NK cells from malignant pleural effusions are not anergic but produce cytokines and display strong antitumor activity on short‐term IL‐2 activation
P. Vacca (2013)
10.1038/s41467-019-09307-6
Dissecting heterogeneity in malignant pleural mesothelioma through histo-molecular gradients for clinical applications
Y. Blum (2019)
10.3390/ijms17030322
Asbestos Induces Oxidative Stress and Activation of Nrf2 Signaling in Murine Macrophages: Chemopreventive Role of the Synthetic Lignan Secoisolariciresinol Diglucoside (LGM2605)
R. Pietrofesa (2016)
10.1038/bjc.2017.269
Evaluating the effect of immune cells on the outcome of patients with mesothelioma
S. Chee (2017)
10.1007/s10637-019-00783-7
A phase Ib study of GSK3052230, an FGF ligand trap in combination with pemetrexed and cisplatin in patients with malignant pleural mesothelioma
E. V. van Brummelen (2019)
10.4049/jimmunol.1701041
Metabolic Barriers to T Cell Function in Tumors
A. Sugiura (2018)
Participation of iron and nitric oxide in the mutagenicity of asbestos in hgprt-, gpt+ Chinese hamster V79 cells.
S. H. Park (1998)
a multicentre, openlabel, randomised, non-comparative, phase 2 trial
A Scherpereel (2019)
Cyclooxygenase-2 expression is a novel prognostic factor in malignant mesothelioma.
J. Edwards (2002)
10.1111/j.1365-2249.1994.tb06144.x
Transforming growth factor‐beta 1 (TGF‐β1)‐ and β2‐like activities in malignant pleural effusions caused by malignant mesothelioma or primary lung cancer
J. Maeda (1994)
10.1309/LN2075V7C8K31CH8
Chemokine receptors are infrequently expressed in malignant and benign mesothelial cells.
B. Davidson (2007)
10.1016/j.jtho.2018.10.001
Neoantigenic Potential of Complex Chromosomal Rearrangements in Mesothelioma
A. Mansfield (2019)
10.1038/s41388-018-0153-z
How asbestos drives the tissue towards tumors: YAP activation, macrophage and mesothelial precursor recruitment, RNA editing, and somatic mutations
H. Rehrauer (2018)
10.1080/2162402X.2015.1009285
The tumoral and stromal immune microenvironment in malignant pleural mesothelioma: A comprehensive analysis reveals prognostic immune markers
H. Ujiie (2015)
10.1136/thorax.58.3.198
Regulation of matrix metalloprotease activity in malignant mesothelioma cell lines by growth factors
Z. Liu (2003)
10.1016/j.humpath.2019.02.001
Tumor PD-L1 expression in malignant pleural and peritoneal mesothelioma by Dako PD-L1 22C3 pharmDx and Dako PD-L1 28-8 pharmDx assays.
D. Chapel (2019)
10.1245/s10434-013-3077-4
Malignant Peritoneal Mesothelioma Treated by Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy: Is GLUT1 Expression a Major Prognostic Factor? A Preliminary Study
J. Hommell-Fontaine (2013)
10.1186/1471-2407-13-324
Defect in recruiting effector memory CD8+ T-cells in malignant pleural effusions compared to normal pleural fluid
A. Scherpereel (2013)
American Thoracic Society International Conference Abstracts: American Thoracic Society
CJ Chapman (2011)
topic: mesothelioma and SCLC
W-S Lam (2017)
10.1158/0008-5472.CAN-15-2524
A Chimeric Switch-Receptor Targeting PD1 Augments the Efficacy of Second-Generation CAR T Cells in Advanced Solid Tumors.
X. Liu (2016)
10.1158/1078-0432.CCR-10-2245
High Blood Neutrophil-to-Lymphocyte Ratio Is an Indicator of Poor Prognosis in Malignant Mesothelioma Patients Undergoing Systemic Therapy
S. Kao (2010)
10.1186/1479-5876-11-187
Treatment of malignant pleural mesothelioma by fibroblast activation protein-specific re-directed T cells
P. Schuberth (2013)
10.1016/j.jtho.2016.06.021
Pleural Effusion of Patients with Malignant Mesothelioma Induces Macrophage‐Mediated T Cell Suppression
L. Lievense (2016)
10.1016/J.LUNGCAN.2005.07.010
Expression and prognostic significance of hypoxia-inducible factor 1α (HIF-1α) in malignant pleural mesothelioma (MPM)
A. Klabatsa (2006)
10.1183/09031936.00101008
Local effector failure in mesothelioma is not mediated by CD4+ CD25+ T-regulator cells
C. Jackaman (2009)
10.1172/JCI83092
Human CAR T cells with cell-intrinsic PD-1 checkpoint blockade resist tumor-mediated inhibition.
Leonid Cherkassky (2016)
10.1186/s12885-018-4720-z
Hypoxia promotes acquisition of aggressive phenotypes in human malignant mesothelioma
Myung-Chul Kim (2018)
L-type amino acid transporter 1 (LAT1) expression in malignant pleural mesothelioma.
K. Kaira (2011)
10.1289/EHP.97105S51257
Pleural macrophage recruitment and activation in asbestos-induced pleural injury.
N. Choe (1997)
10.1136/bmj.k3529
Efficacy of PD-1 or PD-L1 inhibitors and PD-L1 expression status in cancer: meta-analysis
X. Shen (2018)
10.1007/s00262-010-0881-6
CD8+ tumor-infiltrating lymphocytes predict favorable prognosis in malignant pleural mesothelioma after resection
N. Yamada (2010)
10.1016/S0140-6736(15)01238-6
Bevacizumab for newly diagnosed pleural mesothelioma in the Mesothelioma Avastin Cisplatin Pemetrexed Study (MAPS): a randomised, controlled, open-label, phase 3 trial
G. Zalcman (2016)
10.1016/S2213-2600(19)30139-0
Nintedanib in combination with pemetrexed and cisplatin for chemotherapy-naive patients with advanced malignant pleural mesothelioma (LUME-Meso): a double-blind, randomised, placebo-controlled phase 3 trial.
G. Scagliotti (2019)
the role of beta1 integrins
J Klominek (1997)
Clinical safety and activity of pembrolizumab in patients with malignant pleural mesothelioma ( KEYNOTE - 028 ) : preliminary results from a non - randomised , open - label , phase 1 b trial
Y Metaxas (2017)
10.1136/thx.2007.085241
EGFR and PDGFR differentially promote growth in malignant epithelioid mesothelioma of short and long term survivors
H. Kothmaier (2007)



This paper is referenced by
Semantic Scholar Logo Some data provided by SemanticScholar